AR012156A1 - BLOQUEADORES NEUROMUSCULARES DERIVADOS DE ISOQUINOLINIO DE ACCION ULTRA CORTA , COMPOSICION QUE LOS CONTIENE, USO DE DICHO COMPUESTO , INTERMEDIARIOS Y PROCESO PARA SU PREPARACIoN. - Google Patents

BLOQUEADORES NEUROMUSCULARES DERIVADOS DE ISOQUINOLINIO DE ACCION ULTRA CORTA , COMPOSICION QUE LOS CONTIENE, USO DE DICHO COMPUESTO , INTERMEDIARIOS Y PROCESO PARA SU PREPARACIoN.

Info

Publication number
AR012156A1
AR012156A1 ARP980101340A ARP980101340A AR012156A1 AR 012156 A1 AR012156 A1 AR 012156A1 AR P980101340 A ARP980101340 A AR P980101340A AR P980101340 A ARP980101340 A AR P980101340A AR 012156 A1 AR012156 A1 AR 012156A1
Authority
AR
Argentina
Prior art keywords
preparation
ultra short
isoquinolinio
intermediaries
compound
Prior art date
Application number
ARP980101340A
Other languages
English (en)
Original Assignee
Cornell Res Foundation Inc
Avera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9706117.0A external-priority patent/GB9706117D0/en
Priority claimed from GBGB9724987.4A external-priority patent/GB9724987D0/en
Application filed by Cornell Res Foundation Inc, Avera Pharmaceuticals Inc filed Critical Cornell Res Foundation Inc
Publication of AR012156A1 publication Critical patent/AR012156A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen agentes bloqueadores neuromusculares de accion ultra corta de la formula (I) que son utiles como relajantes del musculo esquelético duranteel proceso de intubacion de emergencia, cirugía de rutina y los medios postoperatorios,en donde X es halogeno, h es 1 a 2; Y es hidrogeno o metoxi;Z1 y Z2 son metilo; W1 y W2 son átomos de carbono; y A es un anion farmacéuticamente aceptable. También se descubren composiciones farmacéuticasque los contienen, método parain ducir la parálisis utilizando dichos compuestos, uso de dichos compuestos intermediarios y proceso para lapreparacion.
ARP980101340A 1997-03-25 1998-03-24 BLOQUEADORES NEUROMUSCULARES DERIVADOS DE ISOQUINOLINIO DE ACCION ULTRA CORTA , COMPOSICION QUE LOS CONTIENE, USO DE DICHO COMPUESTO , INTERMEDIARIOS Y PROCESO PARA SU PREPARACIoN. AR012156A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9706117.0A GB9706117D0 (en) 1997-03-25 1997-03-25 Ultra-short acting neuromuscular blockers
GBGB9724987.4A GB9724987D0 (en) 1997-11-27 1997-11-27 Ultra-short acting neuromuscular blockers

Publications (1)

Publication Number Publication Date
AR012156A1 true AR012156A1 (es) 2000-09-27

Family

ID=26311255

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101340A AR012156A1 (es) 1997-03-25 1998-03-24 BLOQUEADORES NEUROMUSCULARES DERIVADOS DE ISOQUINOLINIO DE ACCION ULTRA CORTA , COMPOSICION QUE LOS CONTIENE, USO DE DICHO COMPUESTO , INTERMEDIARIOS Y PROCESO PARA SU PREPARACIoN.

Country Status (37)

Country Link
US (2) US6177445B1 (es)
EP (4) EP1526130A1 (es)
JP (3) JP4112016B2 (es)
KR (2) KR100578443B1 (es)
CN (1) CN1203061C (es)
AP (1) AP1797A (es)
AR (1) AR012156A1 (es)
AT (3) ATE430734T1 (es)
AU (2) AU6730598A (es)
BR (1) BR9808422B1 (es)
CA (1) CA2284802C (es)
CO (1) CO4940499A1 (es)
CZ (1) CZ293786B6 (es)
DE (3) DE69830157T2 (es)
DK (2) DK0975599T3 (es)
EA (1) EA002224B1 (es)
EE (1) EE04113B1 (es)
ES (2) ES2210757T3 (es)
HK (1) HK1023342A1 (es)
HR (1) HRP980157B1 (es)
HU (1) HU228230B1 (es)
ID (1) ID22901A (es)
IL (1) IL131918A (es)
IS (2) IS2346B (es)
MA (1) MA26476A1 (es)
MY (1) MY121316A (es)
NO (1) NO314726B1 (es)
NZ (1) NZ337797A (es)
PE (1) PE68399A1 (es)
PL (1) PL190860B1 (es)
PT (2) PT971898E (es)
RS (1) RS49869B (es)
SI (1) SI0975599T1 (es)
TR (1) TR199902330T2 (es)
TW (1) TW505635B (es)
UY (1) UY24933A1 (es)
WO (2) WO1998042675A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662230A (zh) * 2019-03-06 2020-09-15 四川道珍科技有限公司 一类苄基异喹啉化合物、制备方法和用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1526130A1 (en) * 1997-03-25 2005-04-27 Avera Pharmaceuticals, Inc. Substituted isoquinolines as ultra short acting neuromuscular blockers
US6911455B2 (en) * 1999-12-22 2005-06-28 Smithkline Beecham Corporation Methods for preparing pharmaceutical formulations
US6844904B2 (en) * 2002-12-07 2005-01-18 Cubic Corporation Fast PDLC device
EP1684753A2 (en) * 2003-10-28 2006-08-02 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof
US8148398B2 (en) 2006-12-06 2012-04-03 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
BRPI0808272A2 (pt) * 2007-03-08 2014-07-08 Chemagis Ltd "método para cromatograficamente separar o isômero 1r-cis, 1´r-cis de uma mistura de isômeros de (1r-1'r) - atracúrio, besilato de cisatracúrio e isômero 1r-cis, 1'r-cis do besilato de cisatracúrio"
BRPI0808581A2 (pt) * 2007-03-26 2014-09-16 Chemagis Ltd "método para separar cisatracúrio com alta pureza de uma mistura de isômeros de (1r, 1'r) - atracúrio"
WO2008132748A1 (en) * 2007-05-01 2008-11-06 Chemagis Ltd. Process for producing cisatracurium compounds and associated intermediates
WO2009007946A1 (en) * 2007-07-09 2009-01-15 Chemagis Ltd. Process for producing cisatracurium and associated intermediates
CA2685488A1 (en) 2007-05-01 2008-11-06 Chemagis Ltd. Novel isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates
WO2008155752A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
EP2197848A1 (en) 2007-10-29 2010-06-23 Chemagis Ltd. Novel r,r'-atracurium salts
CA2722651A1 (en) * 2008-05-01 2009-11-05 Chemagis Ltd. Cisatracurium derivatives, preparation and uses thereof
US8592451B2 (en) 2009-03-17 2013-11-26 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
WO2011022491A1 (en) 2009-08-19 2011-02-24 Cornell University Cysteine for physiological injection
WO2014005122A2 (en) * 2012-06-29 2014-01-03 Savarese John J Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration
CN103373959A (zh) * 2013-06-14 2013-10-30 安徽省先锋制药有限公司 顺式苄基异喹啉类化合物的制备方法及其用途
WO2014210369A2 (en) * 2013-06-28 2014-12-31 Cornell University Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
CN108375644B (zh) * 2016-12-07 2021-11-30 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂中间体的分析方法
CN108938573B (zh) * 2017-05-26 2021-08-10 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂组合物及其制备方法和用途
CN110776481B (zh) * 2018-07-24 2023-06-16 四川大学华西医院 一类双阳离子化合物及其制备方法和用途
CN109776486A (zh) * 2019-02-26 2019-05-21 武汉松石科技股份有限公司 一种硫酸亚丙酯的制备方法
CN110117297A (zh) * 2019-04-10 2019-08-13 珠海市赛纬电子材料股份有限公司 一种2-磷酸盐基硫酸丙烯酯的制备方法
WO2021115413A1 (zh) * 2019-12-11 2021-06-17 江苏恒瑞医药股份有限公司 神经肌肉阻滞剂及其制备方法
CN111471013B (zh) * 2020-05-26 2021-04-30 朗天药业(湖北)有限公司 一种米库氯铵及其注射液的制备方法
CN111909089B (zh) * 2020-08-14 2023-04-14 广东嘉博制药有限公司 一种米库氯铵对照品的制备方法
CN114057642B (zh) * 2021-12-10 2023-03-28 广东嘉博制药有限公司 一种米库氯铵中间体的合成方法
CN115073373A (zh) * 2022-07-08 2022-09-20 广东嘉博制药有限公司 一种不对称合成（r）-5’-甲氧基劳丹素的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) * 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
JPS5455577A (en) * 1977-08-01 1979-05-02 Masachiyuusetsutsu Gen Hosupit Blocking agent of neuromuscle
US4701460A (en) * 1980-12-17 1987-10-20 Burroughs Wellcome Co. Long duration neuromuscular blocking agents
JPS5899465A (ja) * 1981-11-23 1983-06-13 ザ・ウエルカム・フアウンデ−シヨン・リミテツド イソキノリン誘導体
GB8418303D0 (en) * 1984-07-18 1984-08-22 Wellcome Found Compounds
BG41897A1 (en) * 1985-07-19 1987-09-15 Ivanov Dichlormethylate of n, n'- 4, 10- dioxa- 3, 11- bis- tetrahydropapaverine and method for its preparation
GB9015473D0 (en) * 1990-07-13 1990-08-29 Wellcome Found Neuromuscular blocking agents
JPH04112016A (ja) * 1990-09-03 1992-04-14 Fuji Electric Co Ltd トランスファ成形金型用プランジャ及びトランスファ成形装置
US5240939A (en) * 1991-10-31 1993-08-31 Anaquest, Inc. Nitrogen bridge tetrahydroisoquinolines
EP1526130A1 (en) * 1997-03-25 2005-04-27 Avera Pharmaceuticals, Inc. Substituted isoquinolines as ultra short acting neuromuscular blockers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111662230A (zh) * 2019-03-06 2020-09-15 四川道珍科技有限公司 一类苄基异喹啉化合物、制备方法和用途

Also Published As

Publication number Publication date
YU48399A (sh) 2002-06-19
IL131918A (en) 2005-09-25
DK0971898T3 (da) 2005-09-05
IS8717A (is) 2008-03-03
NO994680L (no) 1999-11-24
ATE254107T1 (de) 2003-11-15
HUP0001556A2 (hu) 2001-04-28
SI0975599T1 (en) 2004-04-30
PT975599E (pt) 2004-03-31
EA199900756A1 (ru) 2000-08-28
DE69840816D1 (de) 2009-06-18
EP0975599B1 (en) 2003-11-12
KR100578443B1 (ko) 2006-05-11
PL190860B1 (pl) 2006-02-28
ATE295351T1 (de) 2005-05-15
JP4112016B2 (ja) 2008-07-02
AU6730598A (en) 1998-10-20
CZ340499A3 (cs) 2000-04-12
AU745382B2 (en) 2002-03-21
DE69830157D1 (de) 2005-06-16
HU228230B1 (en) 2013-02-28
EP0975599A1 (en) 2000-02-02
PE68399A1 (es) 1999-07-23
EP0971898B1 (en) 2005-05-11
DK0975599T3 (da) 2004-03-15
HRP980157A2 (en) 1999-02-28
AP1797A (en) 2007-11-15
EE04113B1 (et) 2003-08-15
EA002224B1 (ru) 2002-02-28
IL131918A0 (en) 2001-03-19
EP1526130A1 (en) 2005-04-27
CO4940499A1 (es) 2000-07-24
CA2284802A1 (en) 1998-10-01
ES2210757T3 (es) 2004-07-01
IS2346B (is) 2008-03-15
US6187789B1 (en) 2001-02-13
KR20050103984A (ko) 2005-11-01
NO994680D0 (no) 1999-09-24
ES2242275T3 (es) 2005-11-01
PL335885A1 (en) 2000-05-22
DE69819703T2 (de) 2004-09-30
TR199902330T2 (xx) 2000-02-21
MA26476A1 (fr) 2004-12-20
HRP980157B1 (en) 2004-10-31
AU7521098A (en) 1998-10-20
ATE430734T1 (de) 2009-05-15
NZ337797A (en) 2001-03-30
JP4112015B2 (ja) 2008-07-02
WO1998042674A1 (en) 1998-10-01
EP1380573A3 (en) 2004-01-21
AP9901658A0 (en) 1999-09-30
CN1257483A (zh) 2000-06-21
NO314726B1 (no) 2003-05-12
JP2008019272A (ja) 2008-01-31
MY121316A (en) 2006-01-28
EP0971898A1 (en) 2000-01-19
TW505635B (en) 2002-10-11
HK1023342A1 (en) 2000-09-08
CA2284802C (en) 2009-06-16
KR20010005621A (ko) 2001-01-15
UY24933A1 (es) 2000-12-29
EE9900424A (et) 2000-04-17
RS49869B (sr) 2008-08-07
EP1380573A2 (en) 2004-01-14
ID22901A (id) 1999-12-16
DE69819703D1 (de) 2003-12-18
PT971898E (pt) 2005-07-29
DE69830157T2 (de) 2006-05-11
KR100554601B1 (ko) 2006-03-03
BR9808422B1 (pt) 2010-08-24
HUP0001556A3 (en) 2002-01-28
US6177445B1 (en) 2001-01-23
CN1203061C (zh) 2005-05-25
BR9808422A (pt) 2000-05-23
IS5185A (is) 1999-09-17
WO1998042675A1 (en) 1998-10-01
EP1380573B1 (en) 2009-05-06
CZ293786B6 (cs) 2004-07-14
JP2002503220A (ja) 2002-01-29
JP2002517168A (ja) 2002-06-11

Similar Documents

Publication Publication Date Title
AR012156A1 (es) BLOQUEADORES NEUROMUSCULARES DERIVADOS DE ISOQUINOLINIO DE ACCION ULTRA CORTA , COMPOSICION QUE LOS CONTIENE, USO DE DICHO COMPUESTO , INTERMEDIARIOS Y PROCESO PARA SU PREPARACIoN.
BR9813973A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição.
ES545842A0 (es) Procedimiento para preparar difosfonatos
NZ331941A (en) Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
NO873351L (no) Haarrensemiddelblanding og anvendelse av denne.
BR9808042A (pt) Composto, composição farmacêutica, e, processo para preparação de compostos.
ES554305A0 (es) Procedimiento para la fabricacion de derivados quinolilglicinamidas
AR002260A1 (es) Compuestos derivados de acido [4-(indazol-3-il)-piperidin-1-il]-acetico, procedimiento para su preparacion, composicion farmacuetica que los contienen,el uso de los mismos en la preparacion de un agente terapeutico, metodo de tratamiento y compuestos intermediarios.
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
ES519690A0 (es) Procedimiento para la obtencion de azolil-fenoxi-tetrahidrofuran-2-iliden-metanos.
AU567018B2 (en) Prazosin-pirbuterol combination for bronchoduation
BR0211425A (pt) Método para a preparação de compostos, e, uso de uma composição
ES492537A0 (es) Procedimiento para la obtencion de pseudo-trisacaridos
ES2032457T3 (es) Procedimiento para la preparacion de un nuevo derivado de sinergistina.
AR016733A1 (es) Procedimiento de preparacion de 4-(3-piridinil)-1h-imidazol, y los compuestos intermedios empleados
ES2187783T3 (es) Derivados de indolina utiles como antagonistas del receptor 5-ht-2c.
ES543799A0 (es) Procedimiento de preparacion de nuevos derivados 1-hidroxi- propilresorcinos provistos de un grupo fenilo sustituido
MX9302429A (es) Nuevas tetralonas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
ES2038612T3 (es) Compuestos de hidroquinolina, composiciones que los contienen y procedimientos para prepararlas.
ES2054234T3 (es) Un procedimiento para la preparacion de derivados indol.
ES543798A0 (es) Procedimiento de preparacion de nuevos derivados 4-hidroxi- -a-etil-benzoles
AU567498B2 (en) 5-phenyl-1h-2,3-dihydro-1,4-benzodiazepine derivatives.
ES511836A0 (es) "procedimiento para la preparacion de nuevos a1-pirrolin-tiolactimeteres".
AR003231A1 (es) Nuevos compuestos imidazolin-2,4-dionas, que en su posicion-1 contienen un radical sustituido, procedimiento para prepararlos, composiciones farmaceuticasque los contienen y aplicacion de dichos compuestos en la preparacion de dichas composiciones.

Legal Events

Date Code Title Description
FG Grant, registration